Company United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for United Therapeutics Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
255.1 ^USD	+8.88%		+7.65%	+16.03%

05-01	Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
05-01	United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	MT

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Number of employees: 1,168

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	1,936	100.0 %	2,328	100.0 %	+20.20%

USD in Million	2022	Weight	2023	Weight	Delta
United States 94.6 %	1,814	93.7 %	2,202	94.6 %	+21.39%
Rest of World 5.4 %	122	6.3 %	125	5.4 %	+2.54%

Managers	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	69	25/06/96
Michael Benkowitz PSD	President	52	31/03/11
James Edgemond DFI	Director of Finance/CFO	56	31/12/12
Dewey Steadman IRC	Investor Relations Contact	-	-
Paul Mahon LAW	General Counsel	60	25/06/96

Members of the board	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	76	31/12/01
Martine Rothblatt CEO	Chief Executive Officer	69	25/06/96
Tommy Thompson BRD	Director/Board Member	81	31/12/09
Judy Olian BRD	Director/Board Member	72	25/06/15
Katherine Klein BRD	Director/Board Member	67	10/11/14
Louis Sullivan BRD	Director/Board Member	90	31/12/01
Christopher Patusky BRD	Director/Board Member	60	23/10/02
Christopher Causey BRD	Director/Board Member	61	31/12/02
Richard Giltner BRD	Director/Board Member	60	28/04/09
Nilda Mesa BRD	Director/Board Member	64	30/10/18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	70,949,710	43,510,960 ( 61.33 %)	26,619,216 ( 37.52 %)	61.33 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.28 %	4,837,089	10.28 %	1 111 M $
Vanguard Fiduciary Trust Co. 9.932 %	4,673,678	9.932 %	1 074 M $
Wellington Management Co. LLP 8.062 %	3,794,010	8.062 %	872 M $
Martine Rothblatt 6.750 %	3,176,439	6.750 %	730 M $
Avoro Capital Advisor LLC 6.075 %	2,858,888	6.075 %	657 M $
Fidelity Management & Research Co. LLC 4.931 %	2,320,417	4.931 %	533 M $
Renaissance Technologies LLC 4.612 %	2,170,214	4.612 %	499 M $
STATE STREET CORPORATION 4.138 %	1,947,177	4.138 %	447 M $
Janus Henderson Investors US LLC 1.851 %	871,055	1.851 %	200 M $
Geode Capital Management LLC 1.657 %	779,762	1.657 %	179 M $

Name	Equities	%	Valuation
CELULARITY INC. 3.66%	796,885	3.66%	4,167,709 $
CLENE INC. 2.23%	2,869,517	2.23%	1,219,545 $

United Therapeutics Corp.

1000 Spring Street

20910, Silver Spring

+301 608 9292

http://www.unither.com

address United Therapeutics Corporation(UTHR)

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

255.1 USD

Average target price

287.8 USD

Spread / Average Target

+12.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+44.30%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
BIO-TECHNE CORPORATION	-4.80%	11.55B
QIAGEN N.V.	-4.38%	9.5B

Other Biotechnology & Medical Research